Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.2952W HIGH $8.54
Volume
259.12 K
Value Traded
1.16 M
Short % Float
10.53%
-2.34%Week
-0.79%1 Month
-17.49%3 Month
-1.57%6 Month
-51.33%5 Year
-51.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
113.11 M
EPS (TTM)
-0.79
P/E Ratio
-
Ent. Value
94.43 M
Total Shares
45.25 M
Float Shares
38.89 M
Insiders
14.05%
Institutions
31.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GNLX Catalyst Timeline
Dated clinical, regulatory and corporate events for Genelux Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Genelux Corporation
123Total events
3Upcoming
22Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲PublicationOlvi-VecPresentation
Publication of case report in Frontiers in Oncology of platinum-relapsed SCLC patient treated with Olvi-Vec-primed immunochemotherapy
Platinum-relapsed Small Cell Lung Cancersource ↗
▲PublicationOlvi-VecPresentation
Publication of translational analysis from VIRO-15 trial in Gynecologic Oncology Reports
platinum-resistant/refractory ovarian cancersource ↗
▲PublicationOlvi-VecPresentation
Publication of translational analyses from VIRO-15 trial in Gynecologic Oncology Reports
ovarian cancersource ↗
◆Topline ReadoutOlvi-VecClinical Data
Topline data from Phase 3 OnPrime/GOG-3076 trial expected in 2H26
platinum-resistant/refractory ovarian cancersource ↗
▲DSMB ReviewOlvi-VecTrial
IDMC recommended continuation of Phase 3 OnPrime/GOG-3076 trial without modification
platinum-resistant/refractory ovarian cancersource ↗
▼Equity OfferingCorporate
Pricing of $20.0 million underwritten public offering of common stock
◆Topline ReadoutOlvi-VecClinical Data
Topline safety and efficacy data for OnPrime/GOG-3076
platinum resistant/refractory ovarian cancersource ↗
▲Interim AnalysisOlvi-VecTrial
Preliminary data reported: disease control rate in NSCLC
non-small cell lung cancersource ↗
▲Runway Guidance UpdateCorporate
Cash and commitments expected to fund operations into Q1 2026
▲Interim AnalysisOlvi-VecTrial
Interim data from initial dose cohort in NSCLC trial
non-small cell lung cancer (NSCLC)source ↗
▲Interim AnalysisOlvi-VecTrial
Interim data from dose-escalation cohorts in SCLC trial
small cell lung cancer (SCLC)source ↗
◆Oral PresentationPresentation
Fireside chat at Piper Sandler 37th Annual Healthcare Conference
◆Interim AnalysisOlvi-VecTrial
Interim data from systemic lung cancer programs expected in Q4 2025
lung cancersource ↗
●Partnership / LicenseOlvi-VecCorporate
Newsoara BioPharma assigned all rights and obligations under license agreement to affiliate Newsoara HYK Biopharmaceuticals
◆Management ChangeCorporate
Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
◆Interim AnalysisOlvi-VecTrial
Interim data from Phase 2 VIRO-25 trial expected by mid-2025
recurrent advanced or metastatic non-small cell lung cancer (NSCLC)source ↗
▲Type D MeetingOlvi-VecFDA Meeting
Completed Type D meeting with FDA regarding Olvi-Vec for ovarian cancer
platinum-resistant/refractory ovarian cancersource ↗
◆Interim AnalysisOlvi-VecTrial
Interim data readout expected mid-2025
non-small cell lung cancersource ↗
◆Topline ReadoutOlvi-VecClinical Data
Topline results of OnPrime Phase 3 registrational trial anticipated
platinum-resistant/refractory ovarian cancersource ↗
●Runway Guidance UpdateCorporate
Cash runway guidance: cash on hand expected to last into Q2 2025
▲Type D MeetingOlvi-VecFDA Meeting
Type D meeting with FDA for Olvi-Vec in PRROC
Platinum Resistant/Refractory Ovarian Cancersource ↗
▲Topline ReadoutOlvi-VecClinical Data
Preliminary Phase 1b dose escalation data announced
platinum-relapsed or platinum-refractory extensive small cell lung cancersource ↗
◆Enrollment UpdateOlvi-VecTrial
Enrollment continues in dose escalation cohorts
platinum-relapsed or platinum-refractory extensive small cell lung cancersource ↗
▲Type D MeetingOlvi-VecFDA Meeting
Type D meeting with FDA for Olvi-Vec in PRROC
platinum resistant/refractory ovarian cancersource ↗
▼Equity OfferingCorporate
Completed underwritten offering of 3,000,000 shares at $3.50 per share
◆Interim AnalysisOlvi-VecTrial
Interim data from Phase 1b portion of SCLC trial anticipated by end of 2024
recurrent small cell lung cancer (SCLC)source ↗
▲Trial InitiationOlvi-VecTrial
Initiated Phase 2 VIRO-25 trial in NSCLC
recurrent advanced or metastatic non-small cell lung cancer (NSCLC)source ↗
◆Oral PresentationPresentation
Fireside chat at Guggenheim Inaugural Healthcare Innovation Conference
▲First Patient DosedOlvi-VecTrial
First patient dosed in Phase 2 VIRO-25 trial of Olvi-Vec in NSCLC
non-small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How GNLX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Olvi-Vec (olvimulogene nanivacirepvec) | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$40M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 36%
Micro Cap(rank 238 of 658)
Percentile Rank
Genelux Corporation carries a moderate pipeline score (41/100), with $750M risk-adjusted pipeline value, led by Olvimulogene nanivacirepvec in Advanced Non-squamous Non-small-cell Lung Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Olvimulogene nanivacirepvec Gene therapyNCT05281471 | Platinum-resistant Ovarian Cancer | Phase 3 | RECRUITING | 186 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every GNLX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Olvi-Vec Fast Track | platinum-relapsed small cell lung cancer | Phase 1b | 2026-09-09 | progression free survival: 16.7 months; tumor size reduction: 84.6%; first line pfs: 14.3 months; first line dor: 13.0 months; tumor reduction after rechallenge: -78.9%; first line tumor reduction: -67.8%; absolute reduction: 22.0 mm; first line absolute reduction: 11.6 mmRead More | Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ImmunochemotherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cappello JosephOfficer (Chief Technical Officer) | Sell | -10,257 318,480 held | $2.74 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GNLX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 0 % | 237.00 K | 100.00 K |
GNLX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GNLX ranks across every disease it competes in
Competitive Position is a premium feature
See how GNLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGNLX News
GNLXGenelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
Genelux Corporation announced a significant case report detailing a platinum-relapsed small cell lung cancer patient who achieved 16.7 months of progression-free survival following treatment with Olvi-Vec and platinum chemotherapy. The patient also experienced an 84.6% reduction in tumor size, suggesting that Olvi-Vec may enhance the effectiveness of chemotherapy. Ongoing trials are evaluating the systemic administration of Olvi-Vec in lung cancer.
Read more →GNLXGenelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
Genelux Corporation reported its second quarter financial results, highlighting ongoing advancements in its clinical programs, particularly for Olvi-Vec in ovarian and lung cancers. The company anticipates topline data from its Phase 3 OnPrime/GOG-3076 trial in the second half of 2026, while also addressing operational capabilities for future commercialization. Financially, Genelux has $18.7 million in cash, expected to sustain operations into early 2027.
Read more →GNLXGenelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
Genelux Corporation announced the publication of findings from its Phase 1b/2 VIRO-15 trial, highlighting the potential of Olvi-Vec to enhance chemotherapy sensitivity in platinum-resistant ovarian cancer. The study demonstrates that Olvi-Vec can modulate the tumor microenvironment and activate immune responses, supporting the ongoing Phase 3 OnPrime/GOG-3076 trial. The findings suggest a promising avenue for improving treatment outcomes in patients with limited options.
Read more →GNLXGenelux Corporation Reports First Quarter Financial Results and Provides Business Updates
Genelux Corporation reported its first quarter financial results, revealing a cash position of $26.3 million expected to support operations into Q1 2027. The company is progressing with its Phase 3 OnPrime/GOG-3076 trial for Olvi-Vec in platinum-resistant ovarian cancer, with topline data anticipated in the second half of 2026. Additionally, Genelux is pursuing systemic lung cancer programs, with updates expected throughout 2026. However, the financial report noted a net loss of $8.9 million, indicating ongoing challenges as operational costs rise.
Read more →GNLXGenelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Genelux Corporation announced its fourth quarter and full year 2025 financial results while providing updates on clinical trials and operations. The company is poised for significant developments in 2026, with topline data from the Phase 3 OnPrime trial for Olvi-Vec expected in the second half of the year. Interim data has shown promise in lung cancer trials, and the recent appointment of Dr. Jason Litten as Chief Medical Officer aims to bolster the clinical development strategy. The company's financial position was strengthened by a successful stock offering, securing $18.5 million to fund ongoing operations.
Read more →GNLXGenelux Corporation to Participate in Upcoming Conferences
Genelux Corporation, a late clinical-stage immuno-oncology company, announced its participation in two upcoming conferences. The company is focused on developing next-generation oncolytic immunotherapies, with its lead product, Olvi-Vec, currently undergoing evaluation in several clinical trials for various cancer types. Webcasts of the events will be available on their Investor Relations website.
Read more →GNLXGenelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Genelux Corporation announced a virtual fireside chat featuring its CEO, CFO, and CMO on January 19, 2026. The chat will be hosted by Titan Partners and will discuss the company's developments in immuno-oncology. Genelux is focused on oncolytic immunotherapies, with ongoing clinical trials for its lead product, Olvi-Vec, in various cancer types.
Read more →GNLXGenelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
Genelux Corporation has announced the pricing of an underwritten public offering, aiming to raise approximately $20 million by selling 6,666,667 shares at $3.00 each. The proceeds will be allocated for general corporate purposes, including R&D and clinical trials. The offering is expected to close on January 9, 2026, pending customary conditions.
Read more →GNLXCorporation Announces Proposed Public Offering of Common Stock
Genelux Corporation has announced its proposed underwritten public offering of common stock, which includes a 30-day option for underwriters to purchase additional shares. This offering is part of its strategy to raise funds as the company advances its clinical-stage immuno-oncology programs. However, the offering is contingent on market conditions and customary closing requirements, leaving its success uncertain. The company specializes in developing oncolytic immunotherapies for challenging solid tumor types, enhancing its capital resources may support these efforts.
Read more →GNLX▼ -23.5%on this news· ran to -40% by day 3shared move
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
Genelux Corporation has reported encouraging interim data from its ongoing trials of Olvi-Vec for lung cancer treatment. In the Phase 1b/2 trial for small cell lung cancer (SCLC), two of three patients in the highest dose cohort showed significant tumor shrinkage. The Phase 2 trial for non-small cell lung cancer (NSCLC) also indicated anti-tumor activity. Further data is expected throughout 2026.
Read more →GNLX▼ -23.5%on this news· ran to -40% by day 3shared move
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
Genelux Corporation has appointed Dr. Jason Litten as Chief Medical Officer, effective January 2, 2026. Dr. Litten will lead clinical development and medical strategy for the company's immunotherapy, Olvi-Vec, which is undergoing pivotal trials for ovarian and lung cancer. His extensive experience in oncology drug development is expected to support Genelux's goals.
Read more →GNLX▲ +5.7%on this news
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
Genelux Corporation will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. CEO Thomas Zindrick and CFO Matt Pulisic will represent the company during the event. Genelux is advancing its oncolytic immunotherapy, Olvi-Vec, through several clinical trials targeting difficult-to-treat cancers.
Read more →GNLX▼ -32.4%on this news
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation reported its third quarter 2025 financial results, highlighting progress in its lung cancer and ovarian cancer programs. The company anticipates interim data from its lung cancer studies in Q4 2025 and topline results from its Phase 3 ovarian cancer trial in the second half of 2026. Despite an increase in net loss and R&D expenses, Genelux remains optimistic about its pipeline and market opportunities.
Read more →GNLXGenelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
Genelux Corporation will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on September 9, 2025. The session will be moderated by Emily Bodnar and will include one-on-one meetings with institutional investors. Genelux is focused on developing oncolytic immunotherapies, with its lead product, Olvi-Vec, being evaluated in multiple clinical trials.
Read more →GNLX▼ -7%on this news
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation announced its financial results for the second quarter of 2025, reporting a net loss of $7.5 million. The company is working on advancing its candidate, Olvi-Vec, with key clinical readouts expected in the near future, especially for platinum-resistant ovarian cancer. Recent collaborations with the FDA could facilitate a traditional approval pathway for their trials. The appointment of Eric Groen as a new executive is anticipated to strengthen Genelux's leadership as it navigates upcoming developments.
Read more →GNLXGenelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
Genelux Corporation has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development, effective July 1, 2025. Groen brings over two decades of experience in the life sciences industry, having previously served as General Counsel at Rani Therapeutics and spent 20 years at Amgen. His expertise is expected to enhance Genelux's strategic growth and development of its lead product, Olvi-Vec.
Read more →GNLX▼ -7.2%on this news· ran to +18% by day 3
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation announced its financial results for the first quarter of 2025, reporting a net loss of $7.5 million while highlighting progress in its clinical programs. The company received positive regulatory feedback from the FDA regarding its Olvi-Vec treatment for platinum-resistant/refractory ovarian cancer and is seeing increased patient enrollment in trials for lung cancer. Genelux also strengthened its finances through a recent equity raise, allowing further advancement of its strategic initiatives amid ongoing clinical trials.
Read more →GNLX▲ +8.5%on this newsshared move
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Genelux Corporation will participate in a fireside chat at the Citizens Life Sciences Conference on May 8, 2025. CEO Thomas Zindrick and CFO Matt Pulisic will discuss the company's clinical-stage programs, including trials for their oncolytic immunotherapy, Olvi-Vec. The event will be webcasted, and one-on-one meetings will be available for institutional investors.
Read more →GNLXGenelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Genelux Corporation announced its fourth quarter and full year 2024 financial results, highlighting significant advancements in its clinical development. The company has reached alignment with the FDA regarding approval pathways for its candidate Olvi-Vec in treating platinum-resistant ovarian cancer, while also reporting promising preliminary data from ongoing trials in small-cell lung cancer. Additionally, Genelux closed a $10.5 million underwritten offering that enhances its financial position. Despite these positive developments, the company reported a net loss of $29.9 million for the year.
Read more →About Genelux Corporation
Headquarters2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
BIOPHARMAWATCH ELITE PLUS
Trade the next GNLX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime